Skip to main content
I

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2026-04-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物2025年度内部控制评价报告
Audit Report / Information Classification · 1% confidence The document is titled “2025年度内部控制评价报告” and provides a standalone internal control evaluation (scope, criteria, conclusions, remediation) as of December 31, 2025. It is not an annual or interim financial report, not a shareholder notice, earnings release, management change, or investment presentation, nor is it merely an announcement of a report. Instead, it constitutes a standalone audit‐style internal control report. Under the provided taxonomy, standalone audit or control evaluation reports are classified as Audit Report / Information (AR).
2026-04-14 Chinese
益方生物董事会审计委员会2025年度履职情况报告
Audit Report / Information Classification · 1% confidence The document is titled “董事会审计委员会2025年度履职情况报告” (Audit Committee’s 2025 Performance Report) and details the audit committee’s oversight activities, auditor re‐appointment, audit process supervision, review of financial reports, and internal control evaluation. This is not the company’s full annual report (10‐K), nor a simple announcement or proxy material. It is specific audit‐related information produced by the board’s audit committee. Therefore it best fits the “Audit Report / Information” category (AR).
2026-04-14 Chinese
益方生物独立董事年度述职报告（戴欣苗）
Governance Information Classification · 1% confidence The document is titled “独立董事 2025 年度述职报告” and is a detailed self-performance and governance disclosure by an independent director, covering board attendance, committee work, communication with auditors, oversight of financial reports, governance practices, and duties performed during the year. It is not a full annual or quarterly financial report, nor is it an announcement of board changes or an earnings release. Instead, it pertains to corporate governance and board oversight practices, which aligns with the “Governance Information (CGR)” category.
2026-04-14 Chinese
君合律师事务所上海分所关于益方生物2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分（第二批）第二个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书
Regulatory Filings Classification · 0% confidence The document is a legal opinion letter issued by a law firm regarding the conditional vesting and cancellation of restricted shares under the company’s 2022 stock incentive plan. It is not an annual or interim financial report, earnings release, or capital/financing update, nor is it a transcript, voting result, or dividend notice. It is not a notice of shareholder vote results itself (DVA) or a proxy statement (PSI), but rather a legal compliance opinion on a governance matter. There is no evidence of a direct filing of financial statements or regulatory stress tests (AR), nor is it purely management discussion (MDA). It is instead a specialized corporate legal opinion attached to the company’s governance filings—i.e., miscellaneous regulatory disclosure—best captured by the fallback category “Regulatory Filings” (RNS).
2026-04-14 Chinese
益方生物2025年度“提质增效重回报”专项行动方案的评估报告暨2026年度“提质增效重回报”专项行动方案
Management Reports Classification · 1% confidence The document is a detailed assessment and forward‐looking action plan issued by the company’s board, outlining execution of the 2025 “quality enhancement and return” initiative, summarizing operational and R&D progress, governance improvements, and strategic objectives for 2026. It is not an earnings release, annual report, regulatory announcement or share issue, but rather a management’s comprehensive report on business trends, execution status, and outlook. This aligns best with “Management Reports (MDA).”
2026-04-14 Chinese
益方生物科技（上海）股份有限公司审计报告及财务报表（2025年度）
Audit Report / Information Classification · 1% confidence The document is titled “审计报告及财务报表” and comprises a standalone audit report issued by BDO China Shu Lun Pan Certified Public Accountants LLP, including audit opinion, key audit matters, auditor responsibilities, and the full set of financial statements for the year ended December 31, 2025. It does not include management discussion, strategy, or shareholder materials characteristic of an Annual Report (10-K). This matches the definition of an Audit Report / Information (AR).
2026-04-14 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.